

Curriculum Vitae

William Roger Keller, M.D.

Assistant Professor, Department of Psychiatry, Geisel School of Medicine at Dartmouth

Date

September 21, 2021

Contact Information

Dartmouth-Hitchcock Medical Center
One Medical Center Drive, Suite 5D
Lebanon, NH 03756

Fax: 603-650-9478

Email: william.r.keller@hitchcock.org

Education

08/1998 - 06/2002 B.A., Mathematics, University of Maryland Baltimore County (Cum Laude)
08/2002 - 06/2006 M.D., University of Texas Southwestern Medical School
02/2019 – 02/2021 M.B.A Indiana University, Kelley School of Business

Post Graduate Education and Training

07/2006 – 06/2011 Residency Research Track, Psychiatry, University of Maryland / Sheppard Pratt
(Mentor Robert Buchanan, MD)
07/2011 – 06/2013 Fellowship, NIMH-Funded (T32) Multidisciplinary Schizophrenia Research
Fellowship, Maryland Psychiatric Research Center, University of Maryland
School of Medicine (Mentor Robert Buchanan, MD)
01/2018 – 10/2018 Breakthrough Leadership Program, Dartmouth-Hitchcock Bill and Sue Conatay
Institute for Transformational Healthcare Leadership

Certifications

2011 Diplomat, American Board of Psychiatry and Neurology (ABPN)
2011 DEA-Recognized Waiver for Prescribing Narcotics for Maintenance or Detoxification
(allows prescription of buprenorphine in an office based setting)

Medical Licensures

2015 New Hampshire, Active
2008 Maryland, Active

Military Service

02/2012 – present Direct Commissioned Officer, Medical Corps, United States Army (Reserve
Component)
Rank: Lieutenant Colonel (O5)
883rd Combat Stress Control, Stockton, Massachusetts

Employment

01/2016 – present Assistant Professor of Psychiatry, Geisel School of Medicine at Dartmouth
07/2013 – 12/2015 Assistant Professor of Psychiatry, University of Maryland School of Medicine
07/2013 – 12/2015 Psychiatrist Baltimore VA Medical Center, Without Compensation Appointment
08/2010 – 03/2013 Staff Psychiatrist, Sheppard Pratt Hospital, Towson, Maryland (part-time)
08/2010 – 03/2013 Psychiatrist on Duty, Baltimore VA Medical Center, Baltimore, Maryland (per
diem)

Professional Society Memberships

2003 - present American Medical Association
2010 - present American Psychiatric Association
2010 - 2015 Maryland Psychiatric Society
2010 - 2015 Maryland State Medical Society
2017 – present New Hampshire Psychiatric Society
2017 – present New Hampshire Medical Society

Honors and Awards

1998 - 2002 Maryland Distinguished Scholar Award, Merit Scholarship
1998 - 2002 President's Fellow Award at University of Maryland Baltimore County, Merit Scholarship
2001 Golden Key National Honor Society
2002 Phi Beta Kappa
2004 Outstanding Presentation at 42nd Medical Student Research Forum
2006 Excellence on the PRITE (Psychiatry Resident in Training Exam)
2007 Excellence on the PRITE (Psychiatry Resident in Training Exam)
2009 Excellence on the PRITE (Psychiatry Resident in Training Exam)
2009 Workshop Fellow American Society of Clinical Psychopharmacology Workshop on Clinical Trials
2011 Taylor Award for Best Resident Research Paper, University of Maryland School of Medicine, Department of Psychiatry
2011 American Psychiatric Institute for Research and Education (APIRE)/Clinical Trials Research Fellowship Award, American Psychiatric Association (stipend \$45,000)
2012 The International Society for CNS Clinical Trials and Methodology New Investigator Award
2012 Seventeenth Annual Research Colloquium Award for Junior Investigators sponsored by American Psychiatric Association APA Workgroup on Research Training
2019 Dartmouth National Science Foundation I-Corps Grant (\$3000 for Commercialization of Technology)

Clinical Activities and Expertise

Board certified psychiatrist with clinical and research focus in the area of chronic and severe mental illness, schizophrenia, and schizoaffective disorder.

Administrative Service

Institutional Service

2007 – 2009 University of Maryland Medical Center Hospital Ethics Committee
2007 Donaldson Brown Psychiatry Resident Retreat Committee
2016 – 2019 Dartmouth Medical School Faculty Council – Psychiatry Junior Representative
2016 – Present Dartmouth Hitchcock Medical Director Inpatient Psychiatry
2016 – Present Psychiatry Residency Program Evaluation Committee
2016 – Present Clinical Competency Committee for Psychiatry Graduate Education

National Service

ad hoc Reviewer
Schizophrenia Bulletin
Clinical Schizophrenia and Related Psychoses
BMJ Case Reports
American Family Physician

Teaching Service

Supervision/Mentoring

- 2011 -2012 Supervisor, University of Maryland School of Medicine, Psychiatry Resident Research Elective; Supervision during research elective with ongoing project evaluating emotions in schizophrenia, recruited participants and administered behavioral tasks
Carol Vidal; 6 months, Mentor 2011 – 2012, 4 contact hours per week
- 2011 – 2012 Supervisor, University of Maryland School of Medicine, MPRC volunteer intern
Supervision during ongoing research project evaluating emotions in schizophrenia, recruited participants and administered behavioral tasks
Yaakov Shugarman; 6 months, Mentor 2011 – 2012, 4 contact hours per week
[Argosy University; Doctor of Psychology; Matriculated Fall 2012]
- 2012 – present Clinical Skills Verification Examiner, American Association of Directors of Psychiatric Residency Training (AADPRT) version of assessment
- 2016 –2020 Supervision of Franklin Pierce University Physician Assistant psychiatry rotation – 1 time per year for 6 weeks

Medical Student Teaching

- 2006 - 2008 Clinical supervision of medical students during their psychiatry clerkship 1 to 2, 3rd year medical students 8 hours/day, 11 months/year
- 2009 - 2010 Moderator Spring Grove Hospital Clinical Case Conference for Junior Psychiatric Residents and Medical Students – 1 resident, 15 3rd year medical students, 4 contact hours/year
- 2009 – 2010 Moderator Medical Student Teaching Introduction to Clinical Medicine Psychiatric Interviewing Skills, 8 2nd year medical students, 3 contact hours/year
- 2014 – 2015 Preceptor 3rd year Medical Student Clerkship for Outpatient Clinic, 24 contact hours/year
- 2015 – 2015 Moderator Medical Student Teaching Introduction to Clinical Medicine Psychiatric Interviewing Skills, 3 2nd year medical students, 3 contact hours/year
- 2016 – 2019 Scientific Basis of Medicine Lecture Psychosis I and II, 2nd year medical students, 2 contact hours per year
- 2016 – Present Clinical supervision of medical students during psychiatry clerkship 1 to 2, 3rd year medical students 8 hours/day, 12 months/year

Psychiatry Resident Teaching

- 2010 - 2014 Lecturer for Senior Psychiatric Residents Advanced Psychopharmacology Class; “Atypical Antipsychotics” and “Treatment Resistant Depression”; – 10 residents, 2 contact hours/year
- 2011 - 2015 Lecturer for Junior Psychiatric Residents Schizophrenia Course; “Course and Prognosis of Schizophrenia” – 10 residents, 1 contact hours/year
- 2013 –2015 Clinical supervisor of psychiatry resident outpatient rotation, 3rd year psychiatry resident, 12 months/year
- 2016 – 2019 Lecturer for Junior Psychiatric Residents Schizophrenia Course, 2nd year psychiatry residents
- 2016 – 2019 Lecturer for Psychiatry Interns Introduction to Psychosis, 1st year psychiatry residents
- 2017 – 2019 Lecturer for Neurology Residents, Neurobiology of Schizophrenia, 1st, 2nd, 3rd year neurology residents – 10 residents, 1 contact hours/year
- 2016 – Present Clinical supervisor of psychiatry resident inpatient rotation, 1st year psychiatry residents, 12 months/year

Grants

Inactive

09/01/2011 – 08/31/2012

PI: Keller, under supervision of Bernard Fischer MD
Infection and Inflammation in Schizophrenia
VISN 5 MIRECC Pilot Grant
Total Direct Costs: \$24,667

Publications

Peer-reviewed journal articles

1. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, **Keller W**. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophrenia Bulletin*. 2010 Jan;36(1):71-93.
2. **Keller WR**, Fischer BA, Carpenter WT Jr. Revisiting the diagnosis of schizophrenia: Where have we been and where are we going? *CNS Neuroscience & Therapeutics*. 2011 Apr;17(2):83-8.
3. Fischer BA, **Keller WR**, Arango C, Pearlson GD, McMahon RP, Meyer WA, Francis A, Kirkpatrick B, Carpenter WT, Buchanan RW. Cortical structural abnormalities in deficit versus nondeficit schizophrenia. *Schizophrenia Research*. 2012 Apr;136(1-3):51-4.
4. Strauss, G.P., Hong, L.E., **Keller, W.R.**, Buchanan, R.W., Gold, J.M., Fischer, B.A., McMahon, R.P., Catalano, L.T., Culbreth, A.J., Carpenter, W.T., Kirkpatrick, B. Factor Structure of the Brief Negative Symptom Scale. *Schizophrenia Research* 2012;142:96-8.
5. Strauss, G.P., **Keller, W.R.**, Buchanan, R.W., Gold, J.M., Fischer, B.A., McMahon, R.P., Catalano, L.T., Culbreth, A.J., Carpenter, W.T., Kirkpatrick, B. Next-Generation Negative Symptom Assessment for Clinical Trials: Validation of the Brief Negative Symptom Scale. *Schizophrenia Research*. 2012;142:88-92.
6. **Keller WR**, Kum LM, Wehring HJ, Koola MM, Buchanan RW, Kelly DL. A review of anti-inflammatory agents for symptoms of schizophrenia. *Journal of Psychopharmacology*. 2013;27:337-42.
7. Strauss GP, Horan WP, Kirkpatrick B, Fischer BA, **Keller WR**, Miski P, Buchanan RW, Green MF, Carpenter WT Jr. Deconstructing negative symptoms of schizophrenia: Avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. *J Psychiatr Res* 2013;47:783-90.
8. Kelly DL, Wehring HJ, Earl AK, Sullivan KM, Dickerson FB, Feldman S, McMahon RP, Buchanan RW, Warfel D, **Keller WR**, Fischer BA, Shim JC. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). *BMC Psychiatry*. 2013 Aug 22;13:214.
9. **Keller WR**, Fischer BA, McMahon R, Meyer W, Blake M, Buchanan RW. Community adherence to schizophrenia treatment and safety monitoring guidelines. *J Nerv Ment Dis*. 2014 Jan;202(1):6-12.
10. **Keller WR**, Vidal C, Park ES, Strauss GP, Fischer BA. The risk of diabetes in deficit schizophrenia. *Clin Schizophr Relat Psychoses*. 2014 Jan;7(4):235-7.

11. Strauss GP, **Keller WR**, Koenig JI, Gold JM, Ossenfort KL, Buchanan RW. Plasma oxytocin levels predict olfactory identification and negative symptoms in individuals with schizophrenia. *Schizophr Res.* 2015 Mar;162(1-3):57-61.
12. Strauss GP, **Keller WR**, Koenig JI, Sullivan SK, Gold JM, Buchanan RW. Endogenous oxytocin levels are associated with the perception of emotion in dynamic body expressions in schizophrenia. *Schizophr Res.* 2015 Mar;162(1-3):52-6.
13. Warren, K.R., **Keller, W.** & Kelly, D.L. (2015). Brief Psychotic Disorder, *British Medical Journal*, online monograph (update): <https://online.epocrates.com/u/29111118/Brief+psychotic+disorder>.
14. Strauss GP, **Keller WR**, Koenig JI, Gold JM, Frost KH, Buchanan RW. Plasma oxytocin levels predict social cue recognition in individuals with schizophrenia. *Schizophr Res.* 2015 Mar;162(1-3):47-51.
15. Buchanan RW, Weiner E, Kelly DL, Gold JM, **Keller WR**, Waltz JA, McMahon RP, Gorelick DA. Risperidone in the Treatment of the Persistent Negative Symptoms of Schizophrenia. *Schizophr Bull.* 2015 Jul;41(4):900-8.
16. Kelly DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Gold JM, Liu F, Warfel D, Vyas G, Richardson CM, Fischer BA, **Keller WR**, Koola MM, Feldman SM, Russ JC, Keefe RS, Osing J, Hubzin L, August S, Walker TM, Buchanan RW. Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. *J Clin Psychopharmacol.* 2015 Aug;35(4):374-81.
17. Hahn B, Harvey AN, Gold JM, Fischer BA, **Keller WR**, Ross TJ, Stein EA. Hyperdeactivation of the Default Mode Network in People With Schizophrenia When Focusing Attention in Space. *Schizophr Bull.* 2016 Sep;42(5):1158-66.
18. Strauss, G.P., Visser, K.H., **Keller, W.R.**, Gold, J.M., Buchanan, R.W. Anhedonia reflects impairment in making relative value judgments between positive and neutral stimuli in schizophrenia. *Schizophrenia Research.* 2018 Feb 27. pii: S0920-9964(18)30090-2.
19. Strauss GP, Chapman HC, **Keller WR**, Koenig JI, Gold JM, Carpenter WT, Buchanan RW. Endogenous oxytocin levels are associated with impaired social cognition and neurocognition in schizophrenia. *J Psychiatr Res.* 2019 May;112:38-43.

Abstracts

1. **Keller WR**, Fischer BA, Meyer W, Blake M, McMahon R, Buchanan RW. Second generation antipsychotics in community treatment for schizophrenia. *Schizophrenia Bulletin.* 2011 Mar;37(suppl 1):98
2. Kreyenbuhl J, Buchanan R, Kelly D, Noel J, Boggs D, Fischer B, Himelhoch S, Fang B, Peterson E, Aquino P, **Keller W.** The 2009 schizophrenia patient outcomes research team (PORT) psychopharmacological treatment recommendations. *International Clinical Psychopharmacology.* 26():e54-e55, September 2011.
3. Fischer BA, Rowland LM, **Keller WR**, Holcomb HH, Buchanan RW. Acamprosate acts as a partial agonist of the NMDA receptor: Evidence from a spectroscopy study in schizophrenia. *ACNP 2011*

4. Fischer BA, **Keller WR**, Vidal C, Park ES, Strauss GP. The risk of diabetes in deficit schizophrenia. *Schiz Bulletin* 2013;39 (suppl 1) 30-1.

Brief Communications

1. **Keller W**, Buchanan RW. Oxytocin and DMXB as Possible Treatments in Schizophrenia. VA Capital Health Care Network (VISN5), Mental Illness Research, Education, and Clinical Center (MIRECC). *MIRECC Matters*. 2009 Feb Volume 10 Issue 1

2. **Keller WR**. Review of *The Recognition and Management of Early Psychosis* edited by Henry J. Jackson and Patrick C. McGorry. New York: Cambridge University Press, 2009. *Journal of Nervous and Mental Disease*. 198(9):696-697, September 2010.

3. **Keller WR**, Vidal C, Park ES, Strauss GP, Fischer BA. The risk of diabetes in deficit schizophrenia [Letter to the Editor]. *Clinical Schizophrenia and Related Psychoses*. 2013 Mar 14:1-7.

4. **Keller WR**, Fischer BA, McMahon R, Meyer W, Buchanan RW. Open-Label Salsalate for the Treatment of Pre-diabetes in People with Schizophrenia [Letter to the Editor]. *Schizophrenia Research* 2013 Jul;147(2-3):408-9

Major Invited Speeches

Local

1. "Leukoariosis was quantitatively compared in Alzheimer's patients and normal controls using MR imaging of the brain."; 42nd Medical Student Research Forum University of Texas Southwestern Medical School, Dallas, TX. 2004

National

1. "Second generation antipsychotics in community treatment for schizophrenia."; 13th International Congress on Schizophrenia Research, Colorado Springs, CO. 2011

Proffered Communications

1. Fischer BA, **Keller WR**, Arango C, Pearlson G, McMahon RP, Meyer W, Francis A, Kirkpatrick B, Carpenter WT, Buchanan RW. Cortical structural abnormalities in deficit versus nondéficit schizophrenia. (Poster presented at the annual meeting of the American College of Neuropsychopharmacology, Miami Beach, FL.) December 2010

2. **Keller WR**, Fischer BA, Meyer W, Blake M, McMahon R, Buchanan RW. Second generation antipsychotics in community treatment for schizophrenia. (Poster presented at University of Maryland School of Medicine, Department of Psychiatry Research Day, Baltimore, MD.) May 2011

3. Fischer BA, Rowland LM, **Keller WR**, Holcomb HH, Buchanan RW. Acamprosate acts as a partial agonist of the NMDA receptor: Evidence from a spectroscopy study in schizophrenia. (Poster presented at the annual meeting of the American College of Neuropsychopharmacology, December 2011, Waikoloa Beach, HI.) December 2011

4. **Keller WR**, McMahon R, Buchanan RW. Salsalate for the Treatment of Pre-diabetes in People with Schizophrenia. (Poster presented at the International Society for CNS Trial and Clinical Methodology, Washington DC) February 2012

5. Catalano, L.T., **Keller, W.R.**, Lee, B.G., Martins, D.O., Adams, J.L., Shugarman, Y.Y., Llerena, K., Gold, J.M., Buchanan, R.W., Strauss, G.P. The nature of emotional experience abnormalities in

schizophrenia: Is it affective ambivalence or negative emotionality? (Poster presented at the Society for Research in Psychopathology, Ann Arbor, MI.) October 2012

6. Strauss, G.P., **Keller, W.R.**, Koenig, J.I., Catalano, L.T., Adams, J.L., Gold, J.M., Buchanan, R.W. Plasma Oxytocin Levels Predict Olfactory Identification and Hedonic Judgments in Individuals with Schizophrenia. (Poster presented at the Society for Research in Psychopathology, Ann Arbor, MI.) October 2012

7. Gregory P. Strauss, **William R. Keller**, James M. Gold, Robert W. Buchanan Associations between peripheral oxytocin levels and impaired social cognition in schizophrenia (Poster presented at the Schizophrenia International Research Conference, Florence, Italy.) April 2014

8. Ariel B. Katz, **William R. Keller**, James M. Gold, Robert W. Buchanan, Gregory P. Strauss Plasma Oxytocin Levels Predict Social Cue Recognition in Schizophrenia (Poster presented Society for Research in Psychopathology, Evanston, IL.) September 2014

9. Kayla M. Whearty, **William R. Keller**, James M. Gold, Robert W. Buchanan, Gregory P. Strauss Emotional Memory Impairment in Schizophrenia: An Encoding or Retrieval Deficit? (Poster presented Society for Research in Psychopathology, Evanston, IL.) September 2014

10. Katherine H. Frost, **William R. Keller**, Robert W. Buchanan, James M. Gold, James I. Koenig, Kathryn Ossenfort, Ariel B. Katz, Gregory P. Strauss Plasma Oxytocin Levels are Associated with Impaired Social Cognition and Neurocognition in Schizophrenia (Poster presented Society for Research in Psychopathology, Fajardo, PR.) November 2014

11. Britta Hahn, Alexander N. Harvey, Bernard A. Fischer, **William R. Keller**, Thomas J. Ross, Elliot A. Stein Nicotinic Modulation of the Default Network of Resting Brain Function in Non-Smokers (Poster presented at American College of Neuropsychopharmacology, Phoenix, AZ.) December 2014

12. Heinz M, Tauber K, Schleyer W, **Keller WR**. A Case of Topiramate Induced Psychosis in a Patient Treated for Seizure Disorder and Comprehensive Literature Review. (Poster presented at British Neuropsychiatry Association, London, England) March 2020